MAP2K1 and pancreatic neoplasm: In this Phase 1 dose-finding study, we investigated the combination of dacomitinib, a potent irreversible ATP-competitive inhibitor of the HER kinase family (in vitro IC50 values of 6.0 nM, 45.7 nM and 74 nM against the human catalytic domains of HER1, HER2 and HER4), with PD-0325901, a highly specific non-ATP-competitive inhibitor of MEK1 and MEK2, in patients with KRASm CRC, NSCLC or pancreatic cancer.